0QSS fundamentals
An in-depth look to PHAXIAM THERAPEUTICS S A EUR1 (POST CONSOLIDATION) operating, investing, and financing activities
0QSS free cash flow for H2 23 is -12.71 M EUR. For 2023, 0QSS free cash flow was -24.58 M EUR and operating cash flow was -24.37 M EUR.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM